CHLORPROMAZINE

First approved in 1954

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19ClN2S
Molecular Weight	318.864
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCN1C2=CC=CC=C2SC3=CC=C(Cl)C=C13

InChI

InChIKey=ZPEIMTDSQAKGNT-UHFFFAOYSA-N

InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/pro/chlorpromazine.html | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display | https://www.drugbank.ca/drugs/DB00477

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16867246 \| https://www.ncbi.nlm.nih.gov/pubmed/25557493 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2849	1.0 nM [IC50]
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2849	3.4 nM [IC50]
Dopamine D1 receptor 106 Target ID: CHEMBL2056 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2849	56.0 nM [Ki]
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2849	12.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 305 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Manic-depressive disease 9 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Acute intermittent porphyria 7 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Nausea and vomiting 19 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957

C_max

Value	Dose	Analyte	Population
4.31 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
37.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
135 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
81.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
247 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
11.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4399487	unknown, unknown		CHLORPROMAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
75 mg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	unhealthy, 52 years (range: 36.5-65.6 years) Health Status: unhealthy Age Group: 52 years (range: 36.5-65.6 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	Sources: https://pubmed.ncbi.nlm.nih.gov/30558470
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

AEs

AE	Significance	Dose	Population
Adverse event	grade 5	100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
Adverse event	grade 5	25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946		inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2E1 1060 P-gp 1741 BCRP 910 UGT2B10 31 OCT2 779 OATP1A2 43	CYP1A2 1197 P-gp 2052	CYP2B 32 CYP3A 142

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637613/	mild [IC50 52.2 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15135088/	weak [IC50 1000 uM]
OATP1A2 43	inhibitor 4027 Sources: https://jpet.aspetjournals.org/content/352/3/552?cited-by=yes&legid=jpet%3B352/3/552	yes [IC50 12 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 14 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 20 uM]
P-gp 1932	inhibitor 4027 Sources: https://link.springer.com/article/10.1007/s00213-006-0437-9?shared-article-renderer	yes [IC50 5.8 uM]
UGT2B10 33	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/dmd/44/3/378.full.pdf#page=6 Page: 6.0	yes [IC50 79 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 9.5 uM]
CYP2B 41	inducer 1966 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes
CYP3A 317	inducer 1966 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
CYP2D6 1388	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S1110863017300228	yes
CYP3A4 1946	substrate 4014 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913737/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573882/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3647	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3647
ChemicalBook	CB5547531	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5547531
eMolecules	730270	https://www.emolecules.com/cgi-bin/more?vid=730270
MolPort	MolPort-001-727-953	https://www.molport.com/shop/molecule-link/MolPort-001-727-953
ZINC	ZINC000000044027	http://zinc15.docking.org/substances/ZINC000000044027

PubMed

Title	Date	PubMed
Frequency of high-risk use of QT-prolonging medications.	2006-06	16178046
Effect of chlorpromazine on bone sialoprotein (BSP) gene transcription.	2006-04-15	16294319
Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases.	2006-04	16205782
Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways.	2006-02-01	16178010
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.	2005-11	16251329
The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system.	2005-09-01	16036225
Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells.	2005-08-04	15924885
Invited review: fluphenazine augments retinal oxidative stress.	2005-08	16117689
New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.	2005-06	15883975
[Thanatogenesis in poisoning with psychopharmaceuticals].	2005-05-11	15881137
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.	2005-05	15821958
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.	2005-03-07	15694263
Non-paracetamol drug-induced fulminant hepatic failure among adults in Scotland.	2005-02	15674093
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.	2005-02	15342952
The phenothiazine drugs inhibit hERG potassium channels.	2005	16051556
Intraoperative preparation of the radial artery for coronary artery bypass grafting.	2005	16037812
Effects of lipopolysaccharide and chlorpromazine on glucocorticoid receptor-mediated gene transcription and immunoreactivity: a possible involvement of p38-MAP kinase.	2004-12	15589393
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.	2004-10	15083255
Oral terbutaline in the management of pharmacologically induced prolonged erection.	2004-10	14999218
Two cases of deep vein thrombosis associated with antipsychotic drug use.	2004-08	15298663
Valproate-induced hyperammonemic encephalopathy.	2004-08	15266186
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.	2004-05-01	15079866
Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.	2004-05	15071359
Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors.	2004-04-15	15135088
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.	2004-04	15052360
Drug-induced liver injury.	2004-03-01	14986274
Spasmodic dysphonia, a rare form of tardive dystonia, induced by low-dose risperidone?	2004-03	14961937
Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.	2004-01	14659985
[Differences in prooxidant effect of neuroleptics haloperidol and aminazine].	2003-12-03	14650217
Dual action of oestrogens on the mouse constitutive androstane receptor.	2003-12-01	12948398
Mechanism of C2-toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis.	2003-10-24	14556742
Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.	2003-10	12883091
Sydenham's chorea may be a risk factor for drug induced parkinsonism.	2003-09	12933958
Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii.	2003-08-01	12837520
[Reversal of multidrug resistance in leukemic cell line K562/AO2 by chlordelazine in vitro].	2003-07	14746680
QTc prolongation: chlorpromazine and high-dosage olanzapine.	2003-06	12866343
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.	2003-06	12788816
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.	2003-05-10	12747876
The steroid-responsive hiccup reflex arc: competitive binding to the corticosteroid-receptor?	2003-04-08	14523351
Variant Creutzfeldt-Jakob disease.	2003-03	12733426
An unusual cause of convulsions in a newborn infant.	1992-12	1473547
[A case of neuroleptic malignant syndrome with acute renal failure].	1992-11	1485575
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.	1992-09	1416885
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.	1992-07	1353247
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.	1992-04-10	1354163
Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimens.	1992-03	1566986
A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.	1992	1509179
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.	1992	1350058
Chlorpromazine: a drug potentially useful for treating mycobacterial infections.	1992	1288966
THE EFFECT OF L-3, 4-DIHYDROXYPHENYLALANINE AND DL-5-HYDROXYTRYPTOPHAN ON RIGIDITY AND TREMOR INDUCED BY RESERPINE, CHLORPROMAZINE AND PHENOXYBENZAMINE.	1964-04	14172950

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day

Route of Administration: Other

In Vitro Use Guide

Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.

Name

Type

Language

CHLORPROMAZINUM

Preferred Name

English

CHLORPROMAZINE

Official Name

English

ESMIND

Common Name

English

CHLORPROMAZINE [MART.]

Common Name

English

2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine

Systematic Name

English

CHLORPROMAZINUM [HPUS]

Common Name

English

Chlorpromazine [WHO-DD]

Common Name

English

NSC-226514

Code

English

SANOPRON

Common Name

English

CHLORPROMAZINE [VANDF]

Common Name

English

chlorpromazine [INN]

Common Name

English

J2.794D

Code

English

SKF-2601A

Code

English

CHLORPROMAZINE [HSDB]

Common Name

English

CHLORPROMAZINE [USP MONOGRAPH]

Common Name

English

NSC-167745

Code

English

PROPAPHENIN

Common Name

English

10H-PHENOTHIAZINE-10-PROPANAMINE, 2-CHLORO-N,N-DIMETHYL-

Systematic Name

English

CPZ

Common Name

English

3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)-N,N-DIMETHYLPROPAN-1-AMINE

Systematic Name

English

LARGACTILOTHIAZINE

Common Name

English

WINTERMIN

Common Name

English

FENACTIL

Common Name

English

CHLORPROMAZINE [ORANGE BOOK]

Common Name

English

THORAZINE

Brand Name

English

NOVOMAZINA

Common Name

English

CHLORPROMAZINE [MI]

Common Name

English

AMINAZINE

Common Name

English

Classification Tree Code System Code

WHO-ATC

N05AA01